MA33704B1 - Anticorps monoclonaux - Google Patents
Anticorps monoclonauxInfo
- Publication number
- MA33704B1 MA33704B1 MA34824A MA34824A MA33704B1 MA 33704 B1 MA33704 B1 MA 33704B1 MA 34824 A MA34824 A MA 34824A MA 34824 A MA34824 A MA 34824A MA 33704 B1 MA33704 B1 MA 33704B1
- Authority
- MA
- Morocco
- Prior art keywords
- fibrinogen
- fibrin
- domain
- antibodies
- vectors
- Prior art date
Links
- 102000009123 Fibrin Human genes 0.000 abstract 3
- 108010073385 Fibrin Proteins 0.000 abstract 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 3
- 102000008946 Fibrinogen Human genes 0.000 abstract 3
- 108010049003 Fibrinogen Proteins 0.000 abstract 3
- 229950003499 fibrin Drugs 0.000 abstract 3
- 229940012952 fibrinogen Drugs 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 2
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- -1 kits Substances 0.000 abstract 1
- 230000002025 microglial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne un anticorps isolé se liant à la fibrine ou au domaine yc du fibrinogène. Dans divers aspects, l'anticorps inhibe l'adhérence microgliale à la fibrine ou au domaine yc du fibrinogène, inhibe la liaison de mac-1 à la fibrine ou au domaine yc du fibrinogène, et/ou réprime les symptômes cliniques de l'encéphalomyélite auto-immune expérimentale (eae). L'invention concerne également diverses méthodes d'utilisation des anticorps, des compositions pharmaceutiques, des kits, des vecteurs, des cellules comprenant les vecteurs, et des procédés de production des anticorps.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24801409P | 2009-10-02 | 2009-10-02 | |
| PCT/US2010/050873 WO2011041518A1 (fr) | 2009-10-02 | 2010-09-30 | Anticorps monoclonaux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33704B1 true MA33704B1 (fr) | 2012-10-01 |
Family
ID=43826649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34824A MA33704B1 (fr) | 2009-10-02 | 2012-04-30 | Anticorps monoclonaux |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8877195B2 (fr) |
| EP (1) | EP2483416B1 (fr) |
| JP (1) | JP5883389B2 (fr) |
| KR (1) | KR101793221B1 (fr) |
| CN (1) | CN102575277B (fr) |
| AR (1) | AR078490A1 (fr) |
| AU (1) | AU2010300559B2 (fr) |
| BR (1) | BR112012008370B8 (fr) |
| CA (1) | CA2774256C (fr) |
| CL (1) | CL2012000788A1 (fr) |
| CO (1) | CO6440561A2 (fr) |
| CR (1) | CR20120127A (fr) |
| CY (1) | CY1118540T1 (fr) |
| DK (1) | DK2483416T3 (fr) |
| DO (1) | DOP2012000089A (fr) |
| EA (1) | EA023477B1 (fr) |
| ES (1) | ES2614939T3 (fr) |
| GE (2) | GEP20166458B (fr) |
| GT (1) | GT201200096A (fr) |
| HR (1) | HRP20170110T1 (fr) |
| HU (1) | HUE031571T2 (fr) |
| IL (1) | IL218621B (fr) |
| IN (1) | IN2012DN03154A (fr) |
| LT (1) | LT2483416T (fr) |
| MA (1) | MA33704B1 (fr) |
| MX (1) | MX2012003811A (fr) |
| MY (1) | MY159359A (fr) |
| NZ (1) | NZ598770A (fr) |
| PH (1) | PH12012500551A1 (fr) |
| PL (1) | PL2483416T3 (fr) |
| PT (1) | PT2483416T (fr) |
| SI (1) | SI2483416T1 (fr) |
| SM (2) | SMT201700083T1 (fr) |
| TN (1) | TN2012000149A1 (fr) |
| TW (1) | TWI511741B (fr) |
| UA (1) | UA108860C2 (fr) |
| WO (1) | WO2011041518A1 (fr) |
| ZA (1) | ZA201202227B (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011056561A1 (fr) | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Procédés et compositions pour la génération et l'utilisation d'anticorps spécifiques à une conformation |
| WO2012125724A1 (fr) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Méthodes et compositions pour le traitement de troubles prolifératifs |
| US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
| WO2012162698A1 (fr) | 2011-05-26 | 2012-11-29 | Beth Israel Deaconess Medical Center, Inc. | Méthodes et compositions dans le traitement de troubles immunitaires |
| EP2858648B1 (fr) | 2012-06-07 | 2018-08-22 | Beth Israel Deaconess Medical Center, Inc. | Procédés et compositions pour inhiber pin1 |
| CA2903091C (fr) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Procedes et compositions pour la generation et l'utilisation d'anticorps specifiques a une conformation |
| EP3091996B1 (fr) | 2014-01-11 | 2024-04-10 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Compositions et procédés de dosage in vitro de l'activité fibrine |
| US10351914B2 (en) | 2014-07-17 | 2019-07-16 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for Pin1-associated disorders |
| WO2016011268A1 (fr) | 2014-07-17 | 2016-01-21 | Beth Israel Deaconess Medical Center, Inc. | Acide tout-trans-rétinoïque (atra) pour moduler l'activité et la stabilité de pin1 |
| US10548864B2 (en) | 2015-03-12 | 2020-02-04 | Beth Israel Deaconess Medical Center, Inc. | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions |
| BR112019022643A2 (pt) * | 2017-05-02 | 2020-05-19 | Nat Cancer Center Japan | conjugado de fármaco-anticorpo anti-fibrina insolúvel clivável por plasmina |
| KR20220161374A (ko) * | 2020-03-31 | 2022-12-06 | 국립연구개발법인 고쿠리츠간켄큐센터 | 피브린에 결합하는 항체 및 당해 항체를 포함하는 의약 조성물 |
| WO2022133028A1 (fr) * | 2020-12-16 | 2022-06-23 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Utilisation d'une immunothérapie ciblant la fibrine pour réduire la pathogenèse du coronavirus |
| WO2022159776A1 (fr) * | 2021-01-21 | 2022-07-28 | Therini Bio, Inc. | Anticorps qui se lient à la fibrine humaine et méthodes d'utilisation |
| EP4355772A4 (fr) * | 2021-06-18 | 2025-07-30 | Therini Bio Inc | Anticorps qui se lient au domaine ?c de la fibrine ou du fibrinogène humain et méthodes d'utilisation |
| AU2022294106A1 (en) * | 2021-06-18 | 2024-01-25 | Therini Bio, Inc. | ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE |
| WO2024044583A1 (fr) * | 2022-08-22 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Anticorps anti-fibrine humains et leurs utilisations |
| EP4676499A2 (fr) * | 2023-03-10 | 2026-01-14 | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone | Procédés et compositions pour l'immunothérapie cellulaire ? fib4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030031675A1 (en) * | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| PL2314620T3 (pl) * | 2004-05-27 | 2013-11-29 | Crucell Holland Bv | Sposób identyfikowania cząsteczek wiążących zdolnych do neutralizowania wirusa wścieklizny |
| US7807645B2 (en) * | 2005-09-23 | 2010-10-05 | The Regents Of The University Of California | Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment |
-
2010
- 2010-09-30 SM SM20170083T patent/SMT201700083T1/it unknown
- 2010-09-30 PL PL10821238T patent/PL2483416T3/pl unknown
- 2010-09-30 EP EP10821238.2A patent/EP2483416B1/fr active Active
- 2010-09-30 MY MYPI2012001408A patent/MY159359A/en unknown
- 2010-09-30 PH PH1/2012/500551A patent/PH12012500551A1/en unknown
- 2010-09-30 MX MX2012003811A patent/MX2012003811A/es active IP Right Grant
- 2010-09-30 AU AU2010300559A patent/AU2010300559B2/en active Active
- 2010-09-30 HR HRP20170110TT patent/HRP20170110T1/hr unknown
- 2010-09-30 ES ES10821238.2T patent/ES2614939T3/es active Active
- 2010-09-30 DK DK10821238.2T patent/DK2483416T3/en active
- 2010-09-30 GE GEAP201013232A patent/GEP20166458B/en unknown
- 2010-09-30 WO PCT/US2010/050873 patent/WO2011041518A1/fr not_active Ceased
- 2010-09-30 NZ NZ598770A patent/NZ598770A/en unknown
- 2010-09-30 HU HUE10821238A patent/HUE031571T2/en unknown
- 2010-09-30 UA UAA201203044A patent/UA108860C2/ru unknown
- 2010-09-30 SI SI201031390A patent/SI2483416T1/sl unknown
- 2010-09-30 PT PT108212382T patent/PT2483416T/pt unknown
- 2010-09-30 EA EA201270416A patent/EA023477B1/ru unknown
- 2010-09-30 LT LTEP10821238.2T patent/LT2483416T/lt unknown
- 2010-09-30 CN CN201080046037.8A patent/CN102575277B/zh active Active
- 2010-09-30 KR KR1020127011293A patent/KR101793221B1/ko not_active Expired - Fee Related
- 2010-09-30 BR BR112012008370A patent/BR112012008370B8/pt active IP Right Grant
- 2010-09-30 GE GEAP201012676A patent/GEP20156214B/en unknown
- 2010-09-30 CA CA2774256A patent/CA2774256C/fr active Active
- 2010-09-30 JP JP2012532307A patent/JP5883389B2/ja active Active
- 2010-10-01 AR ARP100103578A patent/AR078490A1/es not_active Application Discontinuation
- 2010-10-01 TW TW099133559A patent/TWI511741B/zh active
-
2012
- 2012-03-14 IL IL218621A patent/IL218621B/en not_active IP Right Cessation
- 2012-03-16 CR CR20120127A patent/CR20120127A/es unknown
- 2012-03-20 US US13/425,020 patent/US8877195B2/en active Active
- 2012-03-27 ZA ZA2012/02227A patent/ZA201202227B/en unknown
- 2012-03-29 DO DO2012000089A patent/DOP2012000089A/es unknown
- 2012-03-30 GT GT201200096A patent/GT201200096A/es unknown
- 2012-03-30 TN TNP2012000149A patent/TN2012000149A1/en unknown
- 2012-03-30 CL CL2012000788A patent/CL2012000788A1/es unknown
- 2012-04-12 IN IN3154DEN2012 patent/IN2012DN03154A/en unknown
- 2012-04-18 CO CO12064155A patent/CO6440561A2/es active IP Right Grant
- 2012-04-30 MA MA34824A patent/MA33704B1/fr unknown
-
2017
- 2017-01-30 CY CY20171100132T patent/CY1118540T1/el unknown
- 2017-02-08 SM SM201700083T patent/SMT201700083B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33704B1 (fr) | Anticorps monoclonaux | |
| Xie et al. | Control of von Willebrand factor multimer size by thrombospondin-1 | |
| Rieger et al. | ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases | |
| Moore et al. | Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders | |
| Ling et al. | Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling | |
| WO2010009987A3 (fr) | Dosage d'anticorps de diagnostic | |
| BRPI0518994A2 (pt) | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas | |
| David et al. | Factor XIa–specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis | |
| WO2006124641A3 (fr) | Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques | |
| MA30384B1 (fr) | Therapies combinatoires | |
| MA30922B1 (fr) | Anticorps d'agonistes de trkb et leurs utilisations | |
| ATE460430T1 (de) | Kit zur untersuchung von menschlichem niedermolekulargewicht cd14 und antikörper | |
| WO2006090389A3 (fr) | Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes | |
| EA200970052A1 (ru) | 2-(замещенные амино)бензотиазолсульфонамидные ингибиторы вич-протеазы | |
| Kahn et al. | Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin | |
| Petrov et al. | Conformational changes of blood ACE in chronic uremia | |
| Nakamura et al. | Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin | |
| Miller et al. | A Catalytic Domain Exosite (Cys527− Cys542) in Factor XIa Mediates Binding to a Site on Activated Platelets | |
| WO2007022086A3 (fr) | Anticorps et methodes permettant de prevoir la formation de caries dentaires | |
| EA200901590A1 (ru) | Антитела, применяемые в терапии и диагностике рака | |
| Peton et al. | Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells | |
| Becker | Markers of platelet activation and thrombin generation | |
| Patrascu et al. | Therapeutic options in diffuse large B-cell Lymphoma-A retrospective study and review of the literature | |
| WO2007084570A3 (fr) | Bio-essais de haute sensibilité sur la sécrétagonine, et leur utilisation à des fins de diagnostics et de pronostiques | |
| Ansari et al. | Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment by Drugs and Novel Agents. Research & Reviews: Journal of Oncology and Hematology. 2021; 10 (1): 40–55p |